Invivyd, a biopharmaceutical company, granted stock options to 17 newly hired non-executive employees on June 1, 2026, as an inducement for joining the company. The options cover 513,500 shares at an exercise price of $1.22, matching the stock's closing price on the grant date. These options vest over four years and have a 10-year term, aligning with Nasdaq Listing Rule 5635(c)(4) and the company's 2026 Inducement Plan. This move aims to attract and retain talent as Invivyd advances its work in developing antibody treatments for viral diseases like COVID-19.
Alvotech announced pricing and allocation of a $152 million public share offering in the US and a concurrent private placement in Europe at $3.75 per share. The company expects total proceeds up to $165 million if underwriters exercise their full opt...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
The Schall Law Firm has launched an investigation into Oxford Industries following the company's sharp revenue guidance cut on June 10, 2026, which caused a significant drop in its share price. The probe focuses on whether Oxford issued false or misl...
The global market for highway, street, and bridge construction is projected to grow from $1.28 trillion in 2025 to $2.18 trillion by 2035, at a compound annual growth rate of 4.8%. Growth is driven by government infrastructure spending, urbanization,...
Pepeto's presale has rapidly raised over $10.27 million as Bitcoin's price surges past $66,600, fueled by positive market events like the US-Iran ceasefire and renewed ETF inflows. Cathie Wood's bullish Bitcoin price prediction of $1.25 million by 20...
